A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy.

Sichun XiangRongbin ShenJingjing XiangNi ZhuJianyou GuJianping ShenYu ZhangHangping Ge

Published in: Expert opinion on drug safety (2024)

The Ibrutinib-Obinutuzumab combo has the highest risk of infection, atrial fibrillation and myelosuppression, the Ibrutinib-Lenalidomide combo has the highest risk of pyrexia. However, the Ibrutinib-Venetoclax combo has a lower risk of hemorrhage than monotherapy.

Keyphrases

chronic lymphocytic leukemia
combination therapy
adverse drug
atrial fibrillation
heart failure
left atrial
oral anticoagulants
clinical trial
low dose
acute coronary syndrome
newly diagnosed
high dose